聚乙二醇干扰素联合富马酸替诺福韦治疗慢性乙型肝炎的疗效观察  

Observation on the Efficacy of Pegylated Interferon Combined with Tenofovir Fumarate in the Treatment of Chronic Hepatitis B

作　　者：王雪云[1,2] 孙敏 赵巧云[2] 李红军[2] 王先芝[2] 郑玉山[2] 边城[3] WANG Xue-yun;SUN Min;ZHAO Qiao-yun;LI Hong-jun;WANG Xian-zhi;ZHENG Yu-shan;BIAN Cheng(Graduate School,Qingdao University,Qingdao 266071,Shandong,China;Jining Infectious Disease Hospital,Jining 272031,Shandong,China;Department of Infectious Diseases,the Affiliated Hospital of Qingdao University,Qingdao 266071,Shandong,China)

机构地区：[1]青岛大学研究生院,山东青岛266071 [2]济宁市传染病医院,山东济宁272031 [3]青岛大学附属医院感染性疾病科,山东青岛266071

出　　处：《医学信息》2020年第4期144-146,共3页Journal of Medical Information

摘　　要：目的探讨聚乙二醇干扰素α-2b(Peg-INFα-2b)联合富马酸替诺福韦治疗慢性乙型肝炎早期的临床疗效。方法选择2018年6月~2019年6月我院就诊的慢性乙型肝炎患者62例,随机分为对照组(35例)和观察组(27例),对照组给予聚乙二醇干扰素治疗,观察组在此基础上联合替诺福韦治疗。比较两组治疗24周HBsAg定量、HBeAg定量、HBV-DNA定量、ALT、AST、白细胞、中性粒细胞、血小板变化情况。结果治疗24周两组均未出现HBsAg转阴,且两组HBsAg下降幅度比较,差异无统计学意义(P>0.05);实验组HBeAg下降幅度大于对照组,差异有统计学意义(P<0.05);但两组HBeAg转阴率比较,差异无统计学意义(P>0.05)。治疗24周,对照组HBV-DNA转阴率低于观察组,差异有统计学意义(P<0.05)。两组ALT、AST下降幅度,白细胞、中性粒细胞及血小板水平,流感样症状、骨髓抑制及脱发发生率比较,差异均无统计学意义(P>0.05)。结论聚乙二醇干扰素联合富马酸替诺福韦治疗慢性乙型肝炎24周HBV-DNA转阴率高,HBeAg下降幅度大,HBsAg、HBeAg转阴率及患者肝功能改善效果尚不明显,同时两药联用不增加不良反应。Objective To investigate the early clinical efficacy of pegylated interferonα-2b(Peg-INFα-2b)combined with tenofovir fumarate in the treatment of chronic hepatitis B.Methods 62 patients with chronic hepatitis B who were treated in our hospital from June 2018 to June 2019 were randomly divided into a control group(35 cases)and an observation group(27 cases).The control group was treated with pegylated interferon The observation group was combined with tenofovir treatment on this basis.Changes in HBsAg quantification,HBeAg quantification,HBV-DNA quantification,ALT,AST,white blood cells,neutrophils,and platelets were compared between the two groups after 24 weeks of treatment.Results There was no HBsAg to negative in the two groups after 24 weeks of treatment,and there was no significant difference in the decrease in HBsAg between the two groups(P>0.05).The decrease in HBeAg was greater in the experimental group than in the control group,the difference was statistically significant(P<0.05).However,there was no significant difference in the HBeAg to negative rate between the two groups(P>0.05).After 24 weeks of treatment,the HBV-DNA negative rate in the control group was lower than that in the observation group,the difference was statistically significant(P<0.05).There was no significant difference in the decrease in ALT,AST,leukocyte,neutrophil,and platelet levels,the incidence of influenza-like symptoms,bone marrow suppression,and hair loss between the two groups(P>0.05).Conclusion Pegylated interferon combined with tenofovir fumarate in the treatment of chronic hepatitis B has a high HBV-DNA negative rate for 24 weeks,a large decrease in HBeAg,and no significant improvement in HBsAg,HBeAg negative rate and liver function.At the same time,the combination of two drugs did not increase adverse reactions.

关 键 词：慢性乙型肝炎 聚乙二醇干扰素 富马酸替诺福韦 

分 类 号：R512.62[医药卫生—内科学]